CKP Therapeutics

Executive Summary

CKP Therapeutics is a private biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative small molecule therapies for patients with refractory advanced cancers. Founded in 2018, the company aims to extend life expectancy and improve quality of life by targeting tumors that have failed standard treatments. While specific pipeline details and funding history are not publicly disclosed, CKP Therapeutics operates in the competitive oncology space, leveraging expertise in small molecule drug discovery. The company's focus on refractory cancers suggests a novel mechanism of action or improved efficacy over existing therapies. As a private entity with no ticker, CKP Therapeutics remains under the radar, but its mission aligns with high unmet medical needs. The absence of public clinical data or partnerships indicates an early-stage profile, likely in preclinical or IND-enabling phases. Continued progress will depend on securing financing and advancing lead candidates into the clinic.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Candidate30% success
• Q3 2026Series A Financing Announcement40% success